Plain-English translation of NCT07554339 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a new drug, given together with (a type of immunotherapy) in people with advanced non-small cell lung cancer that has a specific gene mutation called KRAS G12C. You would have already completed chemotherapy and radiation before joining. Researchers want to see if adding this medication to your immunotherapy helps you live longer without your cancer growing or coming back.
Advanced lung cancer with this gene mutation is hard to treat, and doctors need better options beyond chemotherapy and radiation alone. This trial is testing whether this medication can work with immunotherapy to improve outcomes for patients like you.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication plus , or a placebo (dummy pill) plus . Neither you nor your doctors would know which group you're in at first. You would visit the clinic regularly for check-ups, blood tests, and scans to see how well the treatment is working and to monitor for any side effects. The study involves about 310 people and will continue until researchers have enough information to see if the new medication helps patients live longer.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States
Argentina